The principle : desensitization through intact skin
Food allergy is common in children and may lead to sometimes severe reactions. Among the treatments currently under development, epicutaneous immunotherapy (EPIT) stands out for its simple concept : using the skin as a route for immune education by repeatedly applying an allergen.
1) What is EPIT ?
EPIT (epicutaneous immunotherapy) involves applying a very small amount of allergen (for example, peanut or milk proteins) to the skin.
The goal is not to allow unrestricted consumption of the food, but to reduce sensitivity in order to increase reaction thresholds and provide better protection against accidental exposures.
2) Why can the skin “learn” tolerance ?
For a long time, the skin was mainly considered a route of sensitization (eczema, etc.). More recent research shows that when the skin is intact, the immune response may instead shift toward desensitization.
An essential point emerging from experimental data is that on intact skin, the immune response induced by EPIT tends to be regulatory (favorable to tolerance) ; on damaged or abraded skin, the response may instead be more “allergic.”
3) How does the allergen act ?
With EPIT, the allergen is deposited on the surface of the skin and remains localized within the superficial layers.
It is locally captured by skin immune cells, particularly Langerhans cells (specialized antigen-presenting cells).
These cells then migrate to the draining lymph nodes and “educate” the immune response.
No significant passage of the allergen into the bloodstream has been demonstrated in this model, which contributes to the favorable safety profile observed.
4) Which tolerance mechanisms are targeted ?
Available data show that EPIT induces the production of regulatory T cells (Tregs), which play a central role in reducing allergic reactivity.
These Tregs :
- Inhibit the Th2-type allergic response ;
- Reduce inflammation in various tissues ;
- May persist over time and contribute to a prolonged effect, with durable immunological changes, possibly also through epigenetic mechanisms (stable modulation of the expression of certain genes involved in allergy).
5) What do studies show ? Efficacy and tolerance
a) Tolerance (safety)
In reported clinical studies, EPIT generally shows a good safety profile.
Adverse effects are mainly :
- Local reactions at the application site : redness, itching, localized eczema ;
- Sometimes lasting for a few days, but most often manageable with topical treatments or antihistamines.
Severe systemic events are described as rare in the literature.
b) Efficacy (desensitization objective)
Efficacy is usually assessed by an increase in the dose triggering a reaction during an oral food challenge (OFC), i.e., the amount of food tolerated before symptoms appear.
- Cow’s milk protein allergy : a pilot study suggests an increase in tolerated doses with good tolerance, although the effect observed over a short duration may not be statistically significant.
- Peanut allergy : several clinical trials show, particularly in children, a notable proportion of patients meeting response criteria (increase in reactivity threshold), with high adherence and a favorable safety profile.
6) For whom, and with what limitations ?
EPIT is an emerging approach that is still under evaluation and development, depending on the allergen, age group, and protocols.
Key points to understand :
- EPIT does not mean an immediate “cure”: the main objective is desensitization and improved protection against accidental exposures ;
- The question of long-term sustained tolerance after treatment discontinuation remains a major research challenge ;
- Treatment must be supervised by an allergist, with strict safety and follow-up rules.
7) In practice
- EPIT involves repeated application of the allergen to intact skin.
- The allergen is handled by skin immune cells, without injection or ingestion.
- Side effects are mainly cutaneous and local.
- Available data support progressive desensitization and a good safety profile, particularly in children.
- Questions remain regarding the maximum level of protection achievable and the optimal duration of treatment.


